make i open new page for u na

Ekuu Mkt o

Mcy56:

The stock is not even fallen as some may be expecting........
Who are those boycotting? Definitely not the moneybags. Maybe it's those guys with kobo-kobo accts.
If Access should fall, then it's going to be due to general market condition and not any boycott.

2% of bank customers have 98% of the deposits.


Just 2% of bank customers have 500k and above in their accounts. Over 99% have 100k and below.

Mcy56:
Fidson 6.50!

The analysts are seeing positive momentum this week.......can't post analysis now.......let's see how it goes......

analysts kwa?

dem don come again!

@ loco u see what we saying about d gsk and fidson now

fidson have done over 70% after pointed it better fundamental than the gsk even though d later is the leader of the sector

gsk doing less than 15%

no matter up/down mkt will still recognse value sooner or later

note : gsk will rise more

emmanuelewumi:



2% of bank customers have 98% of the deposits.


Just 2% of bank customers have 500k and above in their accounts. Over 99% have 100k and below.

Oga, mbok what is going on with Access Bank

RichEstate:
I'm grateful for this interactive office. Pls bring profs and seers back o. Aunty mercy, if not that you are married, I don't mind giving you my daddy. you are priceless. Agbalowomeri...baale jontolo. Paemma. You are all doing well.

Lol. I fit port nah, make I come dey live for daddy's rich estate, make I stop coming to market everyday.

Na joke o......before some people go shout women and money....

currentprice:
@ loco u see what we saying about d gsk and fidson now

fidson have done over 70% after pointed it better fundamental than the gsk even though d later is the leader of the sector

gsk doing less than 15%

no matter up/down mkt will still recognse value sooner or later

note : gsk will rise more

Gsk will handover the Agbara plant by 3rd quarter 2021 to fidson and laverage in other businesses in Nigeria and remain listed.until then,the value in fidson will unfold.

Gsk is the sector leader with less free float shares than fidson.I expect Gsk to gap up far above fidson despite results.

Note:If fidson should close at 6.50 today,I expect Gsk to close above 7.50.

@Loco which other business is GSK looking at going into?

locodemy:


Gsk will handover the Agbara plant by 3rd quarter 2021 to fidson and laverage in other businesses in Nigeria and remain listed.until then,the value in fidson will unfold.

Gsk is the sector leader with less free float shares than fidson.I expect Gsk to gap up far above fidson despite results.

Note:If fidson should close at 6.50 today,I expect Gsk to close above 7.50.

Emefiele, useless as always, is delaying the q3 results of FUGAZ.

zimams:
@Loco which other business is GSK looking at going into?

I don't know o.
I am not a long term investor.
I don't bother to know because once my exit price is met,na to drop Kaya.

locodemy:


Gsk will handover the Agbara plant by 3rd quarter 2021 to fidson and laverage in other businesses in Nigeria and remain listed.until then,the value in fidson will unfold.

Gsk is the sector leader with less free float shares than fidson.I expect Gsk to gap up far above fidson despite results.

Note:If fidson should close at 6.50 today,I expect Gsk to close above 7.50.

GSK is always better positioned than Fidson.

Outsourcing local manufacturing to Fidson, reduces GSK overheads.

Lion123:
Emefiele, useless as always, is delaying the q3 results of FUGAZ.

i dont really understand this CBN....they will delay audited results,now they also delaying unaudited results.

Keep an eye on GSK. Covid vaccine breakthrough could change it's trajectory. I think they have found a vaccine but just trying to go thru the necessary clinical procedures and approval. The way they collecting monies from different countries and promising production of to a billion in 2021 should not be waived off.

PharmAlfred:
Keep an eye on GSK. Covid vaccine breakthrough could change it's trajectory. I think they have found a vaccine but just trying to go thru the necessary clinical procedures and approval. The way they collecting monies from different countries and promising production of to a billion in 2021 should not be waived off.

Will that affect their Nigerian stock?

currentprice:
@ loco u see what we saying about d gsk and fidson now

fidson have done over 70% after pointed it better fundamental than the gsk even though d later is the leader of the sector

gsk doing less than 15%

no matter up/down mkt will still recognse value sooner or later

note : gsk will rise more

I knew u will want to carry GSK in ur head. …but as I told u then, u will not see what I see in that coy.
It will probably be too deep for u. …because u'd only draw ur judgement from the surface, with indicators like Groses, Nets, PEG, PE/EPS, ROE, ROA, NAV, Cash stand etc.
But Extreme fundamentals have gone past that stage. ...as it takes into consideration, several inputs that looks at the overall health of a coy, value accretion and feasible reward discounting risk !!

Let me give u a small hint:
Go and read about coys with –EV/negative enterprise value, CGPR, AER and how value can be taped from looking at the financial print of a company as a collective. …the only exception to this rule(where its not applicable) are coys in the financial services sector.(banks and insurance coys) There are other very powerful indicators though.

I’ll say it again; unless u have a broad knowledge of extreme fundamentals(FA), u can not see what I see in GSK !! …Its very similar to what I saw in NEIMETH before it delivered over 650% ROI.

If u still have doubt on GSK, then lets do a bet in the 7 digit figure(N1M and above), and I’ll put out an in-depth and comprehensive analysis here to show u why it is no doubt, grossly undervalued.
I would’ve just put it up, but I will be given out a few of my FA tips using one of my models. …so I need to be sure that I can make something off it. So that next time, u will stop been a doubting Thomas.

I am waiting bro !!

As I’ve always said in times past, I like it when folks like u have doubt. …but for anything, it helps better my bargaining power over strategic positioning. I am presently on the queue to acquire more GSK, and I will acquire even more. Na make my Oga pay me my minimum wage for last month 1st.
btw, I don't think u understand the melody that's been played in GSK.

Regards

PharmAlfred:
Keep an eye on GSK. Covid vaccine breakthrough could change it's trajectory. I think they have found a vaccine but just trying to go thru the necessary clinical procedures and approval. The way they collecting monies from different countries and promising production of to a billion in 2021 should not be waived off.

does that means that GSK is good to buy now? thanks

Quite some sell off in the market.......
Those selling will still be selling at profit......after many stocks appreciated by 100% and more......
Reason why entry price is important......

Market still awaiting Q3 results, which are long overdue.........

I hope NEIMETH is still partnering with Pfizer

Mcy56:
Quite some sell off in the market.......
Those selling will still be selling at profit......after many stocks appreciated by 100% and more......
Reason why entry price is important......

Market still awaiting Q3 results, which are overdue.....

We are watching

onegentleguy:


I knew u will want to carry GSK in ur head. …but as I told u then, u will not see what I see in that coy.
It will probably be too deep for u. …because u would only draw ur judgement from the surface, with indicators like Groses, nets, PEG, PE, EPS, ROE, ROA, NAV, Cash stand etc.
But Extreme fundamentals have gone past that stage. ..as it takes into consideration, several inputs that looks at the overall health of a coy, value accretion and feasible reward discounting risk !!

Let me give u a small hint:
Go and read about coys with –EV/negative enterprise value, CGPR, AER and how value can be taped from looking at the financial print of a company as a collective. …the only exception to this rule(where its not applicable) are coys in the financial services sector.(banks and insurance coys) There are other very powerful indicators though.

I’ll say it again; unless u have a broad knowledge of extreme fundamentals(FA), u can not see what I see in GSK !! …Its very similar to what I saw in NEIMETH before it delivered over 650% ROI.

If u still have doubt on GSK, then lets do a bet in the 7 digit figure(N1M and above), and I’ll put out an in-depth and comprehensive analysis here to show u why it is no doubt, grossly undervalued.
I would’ve just put it up, but I will be given out a few of my FA tips using one of my models. …so I need to be sure that I can make something off it. So that next time, u will stop been a doubting Thomas.

I am waiting bro !!

Btw, as I’ve always said in times past, I like it when folks have doubt. …but for anything, it helps better my bargaining power over strategic positioning. I am presently on the queue to acquire more GSK, and I will acquire even more. Na make my Oga pay me my minimum wage for last month 1st. ;

Regards

no be competition nor fight bro. I use what works for me. you can use what ever work for you to kill the market.

currentprice:


no be competition nor fight bro. I use what works for me. you can use what ever work for you to kill the market.

Ok bro... though I for like make we do the bet so that next time, u'll stop been a doubting Thomas !!

Regards

PharmAlfred:
Keep an eye on GSK. Covid vaccine breakthrough could change it's trajectory. I think they have found a vaccine but just trying to go thru the necessary clinical procedures and approval. The way they collecting monies from different countries and promising production of to a billion in 2021 should not be waived off.

Heard that Canada and 2 other European countries made a $1 billion and $2.1 billion respective upfront payments to GLAXOSMITKLINE(GSK), PFIZER and JOHNSON & JOHNSON(J&J) for the early provision of covid-19 vaccine to ensure early access on usage.
The 1st coy(GSK) has a subset quoted on the NSE, while the 2nd is affiliated to NEIMETH, another quoted coy on the exchange.

Beyond this though, GSK is grossly underpriced !!

Selah

onegentleguy:


I knew u will want to carry GSK in ur head. …but as I told u then, u will not see what I see in that coy.
It will probably be too deep for u. …because u would only draw ur judgement from the surface, with indicators like Groses, nets, PEG, PE, EPS, ROE, ROA, NAV, Cash stand etc.
But Extreme fundamentals have gone past that stage. ..as it takes into consideration, several inputs that looks at the overall health of a coy, value accretion and feasible reward discounting risk !!

Let me give u a small hint:
Go and read about coys with –EV/negative enterprise value, CGPR, AER and how value can be taped from looking at the financial print of a company as a collective. …the only exception to this rule(where its not applicable) are coys in the financial services sector.(banks and insurance coys) There are other very powerful indicators though.

I’ll say it again; unless u have a broad knowledge of extreme fundamentals(FA), u can not see what I see in GSK !! …Its very similar to what I saw in NEIMETH before it delivered over 650% ROI.

If u still have doubt on GSK, then lets do a bet in the 7 digit figure(N1M and above), and I’ll put out an in-depth and comprehensive analysis here to show u why it is no doubt, grossly undervalued.
I would’ve just put it up, but I will be given out a few of my FA tips using one of my models. …so I need to be sure that I can make something off it. So that next time, u will stop been a doubting Thomas.

I am waiting bro !!

As I’ve always said in times past, I like it when folks like u have doubt. …but for anything, it helps better my bargaining power over strategic positioning. I am presently on the queue to acquire more GSK, and I will acquire even more. Na make my Oga pay me my minimum wage for last month 1st.
btw, I don't think u understand the melody that's been played in GSK.

Regards

Believe NEIMETH is still undervalued.

onegentleguy:


Ok bro... though I for like make we do the bet, so that next time, u'll stop been a doubting Thomas !!

Regards

use the money to add more unit of ur choice stock to your portfolio or if you must bet then go betnaija

currentprice:


use the money to add more unit of ur choice stock to your portfolio or if you must bet then go betnaija

I am on GSK queue.
Abeg help me bad mouth the coy, so that folks can sell down to my position.
Na only 2 afolabi unit I wan buy.

onegentleguy:


I knew u will want to carry GSK in ur head. …but as I told u then, u will not see what I see in that coy.
It will probably be too deep for u. …because u would only draw ur judgement from the surface, with indicators like Groses, nets, PEG, PE, EPS, ROE, ROA, NAV, Cash stand etc.
But Extreme fundamentals have gone past that stage. ..as it takes into consideration, several inputs that looks at the overall health of a coy, value accretion and feasible reward discounting risk !!

Let me give u a small hint:
Go and read about coys with –EV/negative enterprise value, CGPR, AER and how value can be taped from looking at the financial print of a company as a collective. …the only exception to this rule(where its not applicable) are coys in the financial services sector.(banks and insurance coys) There are other very powerful indicators though.

I’ll say it again; unless u have a broad knowledge of extreme fundamentals(FA), u can not see what I see in GSK !! …Its very similar to what I saw in NEIMETH before it delivered over 650% ROI.

If u still have doubt on GSK, then lets do a bet in the 7 digit figure(N1M and above), and I’ll put out an in-depth and comprehensive analysis here to show u why it is no doubt, grossly undervalued.
I would’ve just put it up, but I will be given out a few of my FA tips using one of my models. …so I need to be sure that I can make something off it. So that next time, u will stop been a doubting Thomas.

I am waiting bro !!

As I’ve always said in times past, I like it when folks like u have doubt. …but for anything, it helps better my bargaining power over strategic positioning. I am presently on the queue to acquire more GSK, and I will acquire even more. Na make my Oga pay me my minimum wage for last month 1st.
btw, I don't think u understand the melody that's been played in GSK.

Regards

Someone like u shouldn't be working for any Oga, you are supposed to be running ur own hedge fund.

Have u thought along this line@OGG?
Pls do if u ve never.

ositadiima1:


Someone like u shouldn't be working for any Oga, you are supposed to be running ur own hedge fund.

I don't understand anymore oo... this one still be retracement or gear changed to reversal?

onegentleguy:


I knew u will want to carry GSK in ur head. …but as I told u then, u will not see what I see in that coy.
It will probably be too deep for u. …because u'd only draw ur judgement from the surface, with indicators like Groses, nets, PEG/PE, EPS, ROE, ROA, NAV, Cash stand etc.
But Extreme fundamentals have gone past that stage. ...as it takes into consideration, several inputs that looks at the overall health of a coy, value accretion and feasible reward discounting risk !!

Let me give u a small hint:
Go and read about coys with –EV/negative enterprise value, CGPR, AER and how value can be taped from looking at the financial print of a company as a collective. …the only exception to this rule(where its not applicable) are coys in the financial services sector.(banks and insurance coys) There are other very powerful indicators though.

I’ll say it again; unless u have a broad knowledge of extreme fundamentals(FA), u can not see what I see in GSK !! …Its very similar to what I saw in NEIMETH before it delivered over 650% ROI.

If u still have doubt on GSK, then lets do a bet in the 7 digit figure(N1M and above), and I’ll put out an in-depth and comprehensive analysis here to show u why it is no doubt, grossly undervalued.
I would’ve just put it up, but I will be given out a few of my FA tips using one of my models. …so I need to be sure that I can make something off it. So that next time, u will stop been a doubting Thomas.

I am waiting bro !!

As I’ve always said in times past, I like it when folks like u have doubt. …but for anything, it helps better my bargaining power over strategic positioning. I am presently on the queue to acquire more GSK, and I will acquire even more. Na make my Oga pay me my minimum wage for last month 1st.
btw, I don't think u understand the melody that's been played in GSK.

Regards

How Yahoo finance describes coys with -EV;

"For a company to have a negative enterprise value, it has to have more cash on its balance sheet than its market value and debt. This could imply that the company is hugely undervalued. It deserves a case-by-case analysis of the situation and the company's strengths or weaknesses...
Simply put, a negative enterprise value means that a company has more cash than it would need to pay off any debt and buy back all its stocks in one go, if it really wanted to."

That said, there are other very powerful indicators too. ...aside -EV, there are at least 6 other powerful/key determinants that clearly shows the hugely undervalued stand of GSK !!
That coy should have no business trading below N12.90.
As I said before, the present mkt price is by far, way too cheap !! Feasible REWARD is clearly making a mockery of risk(RR in view)
If the coy were to be selling for N11.70 or an 8-10.5% discount from that price, then we could begin to attach an intrinsic peg to it, but which(compared to peers) would even still be underpriced.

Selah

swilo:


Veecovid.. good morning.

covid?